The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

In another milestone, Eli Lilly's weight-loss medication, Zepbound, received FDA approval, marking it as the first drug to specifically tackle moderate to severe obstructive sleep apnea in obese ...

Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...

Eli Lilly's Zepbound has become the first drug to be FDA-approved for obstructive sleep apnoea (OSA), a sleep-related ...

Additionally, Eli Lilly's weight-loss drug gains FDA approval for sleep apnea, amidst growing competition from licensed drug ...

Novo Nordisk and Eli Lilly are currently a duopoly in the obesity market, which reached a value of $24 billion last year ...

Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...

"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity." ...

India’s apex drug regulating authority, the Central Drugs Standard Control Organisation (CDSCO), has approved 19 new drugs so ...

The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.